logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — Osimertinib is highly effective in EGFR mutation-positive resectable NSCLC

Prolonged DFS and reduced CNS disease recurrence in EGFR+ NSCLC under osimertinib after resection.